Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

Race Oncology is pleased to release an investor webinar video, where Race’s Executive Chair, Dr Peter Smith and CEO and Managing Director, Dr Daniel Tillett take a deep dive into (E,E)-bisantrene’s Mechanism of Action (MOA) as a G-quadruplex binder. This session covers the MOA’s potent impact on the "undruggable" MYC oncogene and the significance of its discovery for Race’s partnering / licensing activities. The webinar also includes investor Q&A.

Race Oncology Investor Briefing - Anticancer MOA webinar, Wednesday October 8, 2025